| Literature DB >> 26950362 |
Aharon Helman1, Agnes Klochendler1, Narmen Azazmeh1, Yael Gabai1, Elad Horwitz1, Shira Anzi1, Avital Swisa1, Reba Condiotti1, Roy Z Granit1, Yuval Nevo2, Yaakov Fixler1, Dorin Shreibman1, Amit Zamir1, Sharona Tornovsky-Babeay3, Chunhua Dai4, Benjamin Glaser3, Alvin C Powers4,5,6, A M James Shapiro7,8, Mark A Magnuson5,9, Yuval Dor1, Ittai Ben-Porath1.
Abstract
Cellular senescence is thought to contribute to age-associated deterioration of tissue physiology. The senescence effector p16(Ink4a) is expressed in pancreatic beta cells during aging and limits their proliferative potential; however, its effects on beta cell function are poorly characterized. We found that beta cell-specific activation of p16(Ink4a) in transgenic mice enhances glucose-stimulated insulin secretion (GSIS). In mice with diabetes, this leads to improved glucose homeostasis, providing an unexpected functional benefit. Expression of p16(Ink4a) in beta cells induces hallmarks of senescence--including cell enlargement, and greater glucose uptake and mitochondrial activity--which promote increased insulin secretion. GSIS increases during the normal aging of mice and is driven by elevated p16(Ink4a) activity. We found that islets from human adults contain p16(Ink4a)-expressing senescent beta cells and that senescence induced by p16(Ink4a) in a human beta cell line increases insulin secretion in a manner dependent, in part, on the activity of the mechanistic target of rapamycin (mTOR) and the peroxisome proliferator-activated receptor (PPAR)-γ proteins. Our findings reveal a novel role for p16(Ink4a) and cellular senescence in promoting insulin secretion by beta cells and in regulating normal functional tissue maturation with age.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26950362 PMCID: PMC5546206 DOI: 10.1038/nm.4054
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440